Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study

Abstract

BackgroundFew studies have investigated the 24-hour symptom profile in patients with COPD or how symptoms during the 24-hour day are inter-related. This observational study assessed the prevalence, severity and relationship between night-time, early morning and daytime COPD symptoms and explored the relationship between 24-hour symptoms and other patient-reported outcomes.MethodsThe study enrolled patients with stable COPD in clinical practice. Baseline night-time, early morning and daytime symptoms (symptom questionnaire), severity of airflow obstruction (FEV1), dyspnoea (modified Medical Research Council Dyspnoea Scale), health status (COPD Assessment Test), anxiety and depression levels (Hospital Anxiety and Depression Scale), sleep quality (COPD and Asthma Sleep Impact Scale) and physical activity level (sedentary, moderately active or active) were recorded.ResultsThe full analysis set included 727 patients: 65.8% male, mean ± standard deviation age 67.2 ± 8.8 years, % predicted FEV1 52.8 ± 20.5%.In each part of the 24-hour day, >60% of patients reported experiencing ≥1 symptom in the week before baseline. Symptoms were more common in the early morning and daytime versus night-time (81.4%, 82.7% and 63.0%, respectively). Symptom severity was comparable for each period assessed. Overall, in the week before baseline, 56.7% of patients had symptoms throughout the whole 24-hour day (3 parts of the day); 79.9% had symptoms in ≥2 parts of the 24-hour day. Symptoms during each part of the day were inter-related, irrespective of disease severity (all p < 0.001).Early morning and daytime symptoms were associated with the severity of airflow obstruction (p < 0.05 for both). Night-time, early morning and daytime symptoms were all associated with worse dyspnoea, health status and sleep quality, and higher anxiety and depression levels (all p < 0.001 versus patients without symptoms in each corresponding period). In each part of the 24-hour day, there was also an association between symptoms and a patient’s physical activity level (p < 0.05 for each period).ConclusionsMore than half of patients experienced COPD symptoms throughout the whole 24-hour day. There was a significant relationship between night-time, early morning and daytime symptoms. In each period, symptoms were associated with worse patient-reported outcomes, suggesting that improving 24-hour symptoms should be an important consideration in the management of COPD.Electronic supplementary materialThe online version of this article (doi:10.1186/s12931-014-0122-1) contains supplementary material, which is available to authorized users.

A study of the clinical profile of 50 patients of COPD with correlation between clinical, radiological and spirometric evaluation

“…Chronic and progressive dyspnoea is the cardinal symptom of COPD and a major cause of disability in these patients. 8 A simple measure of dyspnoea is the Modified British Medical Research Council (mMRC) Questionaire. 9 The mMRC questionnaire relates well to other measures of health status and predicts future mortality risk.…”

Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?

“…The recent observational ASSESS study, which included more than 700 patients with COPD, performed in a real-life context, has confirmed the significant prevalence of nighttime symptoms (52%), which tend to be associated both with greater symptom severity, as assessed by the COPD Assessment Test (CAT), and higher prevalence of anxiety and depression, as assessed by the Hospital Anxiety and Depression Scale (HADS) [16]. In the clinical practice, however, the circadian variability is often not adequately taken into consideration in the therapeutic approach; for example, a real-life clinical study showed that drug treatment was not changed in more than half of patients surveyed, even though a significant worsening of symptoms over 24 h was noted.…”

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

“…The PKs of GFF MDI support twice-daily administration and the improvements in lung function demonstrated here after BID dosing with GFF MDI as maintenance dual-bronchodilator therapy may provide benefits over QD dosing, preventing excessive worsening of symptoms during the night or towards the morning in patients with this pattern of symptoms [7]. The results of a patient evaluation survey conducted by Partridge et al, and similarly in the ASSESS study, show that patients with COPD begin to experience worsening symptoms in the evening through the night-time, with the worst symptoms, affecting activity and productivity, occurring in the morning [22, 23]. This is also an area for future investigation of the effects of GFF MDI on COPD symptom burden.…”